535 lung cancer patients studied to see how nivolumab performs after chemo
NCT ID NCT04500535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 535 people in France with advanced non-small cell lung cancer who were given nivolumab after at least one round of chemotherapy. Researchers wanted to see how well the drug worked, how long it kept cancer from getting worse, and what side effects occurred in everyday medical practice. The goal was to gather real-world information, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
535 people
The number who actually took part.
- Started
-
Sep 2020
- Finished
-
Apr 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The target population will be constituted using multistage sampling, in which physicians (pulmonologists and/or oncologists) from eligible hospitals are to identify and recruit the participants. Eligible hospitals will be selected among PMSI sites (national hospital discharge database) and only hospitals with a minimum of 40 patients treated for lung cancer and with chemotherapy in 2018 will be considered to ensure sufficient enrollment.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Pathologically confirmed diagnosis of advanced NSCLC * Whose physician has already decided to initiate a treatment with nivolumab for the treatment of advanced NSCLC according to the European label * Previously treated with at least one prior chemotherapy- containing regimen Exclusion Criteria: * Participants taking part in an interventional study for lung cancer treatment for which nivolumab is one of the investigational drugs * Participants with a diagnosis of another primary cancer within the past five years * Participants receiving IO within 12 weeks prior to nivolumab first infusion in the context of the present study Other protocol-defined inclusion/exclusion criteria apply
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Local Institution - 0001
Paris, 75248, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A dose-escalation, dose-extension and efficacy-extension, phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of AP-L1898 capsule for the treatment of the patients with locally advanced or metastatic non-small cell lung cancer
- Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide
- Increasing equity in lung cancer screening
- A spoonful of olive oil before lung surgery: a new shield against a rare complication?
- Mobile lung cancer clinics aim to close rural screening gap
- Can protein patterns in stored tumors point to new treatment targets?